Inozyme Pharma (NASDAQ:INZY) Rating Reiterated by Wedbush

Inozyme Pharma (NASDAQ:INZY)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a research note issued on Tuesday, RTT News reports. They currently have a $15.00 price objective on the stock. Wedbush’s price target suggests a potential upside of 234.08% from the company’s previous close.

A number of other research firms have also weighed in on INZY. Wells Fargo & Company initiated coverage on shares of Inozyme Pharma in a research note on Thursday, May 30th. They issued an “overweight” rating and a $14.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Inozyme Pharma in a research note on Wednesday, May 8th. Bank of America reduced their price objective on shares of Inozyme Pharma from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, April 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Inozyme Pharma in a research note on Tuesday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $16.00.

Inozyme Pharma Trading Up 1.6 %

Shares of INZY stock opened at $4.49 on Tuesday. The company has a 50 day moving average of $4.60 and a 200-day moving average of $5.09. The company has a quick ratio of 14.05, a current ratio of 14.05 and a debt-to-equity ratio of 0.38. Inozyme Pharma has a 12-month low of $2.69 and a 12-month high of $7.80. The firm has a market cap of $277.75 million, a P/E ratio of -3.28 and a beta of 1.53.

Inozyme Pharma (NASDAQ:INZY) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.03). Sell-side analysts anticipate that Inozyme Pharma will post -1.59 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of INZY. Values First Advisors Inc. bought a new position in Inozyme Pharma in the 4th quarter valued at $59,000. SG Americas Securities LLC boosted its holdings in Inozyme Pharma by 46.9% in the 4th quarter. SG Americas Securities LLC now owns 21,236 shares of the company’s stock valued at $90,000 after purchasing an additional 6,784 shares during the period. Superstring Capital Management LP bought a new position in Inozyme Pharma in the 4th quarter valued at $528,000. Schonfeld Strategic Advisors LLC boosted its holdings in Inozyme Pharma by 346.8% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 311,880 shares of the company’s stock valued at $1,310,000 after purchasing an additional 242,080 shares during the period. Finally, Laurion Capital Management LP boosted its holdings in Inozyme Pharma by 170.5% in the 3rd quarter. Laurion Capital Management LP now owns 677,329 shares of the company’s stock valued at $2,845,000 after purchasing an additional 426,961 shares during the period. 88.30% of the stock is owned by institutional investors.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.